Location First: Targeting Acute Myeloid Leukemia Within Its Niche

• Published in: Journal of clinical medicine Vol. 9; no. 5; p. 1513
• Main Authors: Pievani, Alice, Biondi, Marta, Tomasoni, Chiara, Biondi, Andrea, Serafini, Marta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.05.2020; MDPI
• Subjects: acute myeloid leukemia (AML); Antibodies; Antigens; Apoptosis; bone marrow niche; bone marrow stromal cells; Cell adhesion & migration; Cell growth; Chemotherapy; Clinical medicine; Cyclin-dependent kinases; Disease; Immune system; Kinases; Leukemia; leukemic stem cell (LSC); Medical prognosis; Mutation; Retention; Review; Stem cells; targeted therapy; bone marrow stromal cells; targeted therapy; acute myeloid leukemia (AML); leukemic stem cell (LSC); bone marrow niche
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm9051513

Despite extensive research and development of new treatments, acute myeloid leukemia (AML)-backbone therapy has remained essentially unchanged over the last decades and is frequently associated with poor outcomes. Eradicating the leukemic stem cells (LSCs) is the ultimate challenge in the treatment of AML. Emerging evidence suggests that AML remodels the bone marrow (BM) niche into a leukemia-permissive microenvironment while suppressing normal hematopoiesis. The mechanism of stromal-mediated protection of leukemic cells in the BM is complex and involves many adhesion molecules, chemokines, and cytokines. Targeting these factors may represent a valuable approach to complement existing therapies and overcome microenvironment-mediated drug resistance. Some strategies for dislodging LSCs and leukemic blasts from their protective niche have already been tested in patients and are in different phases of the process of clinical development. Other strategies, such as targeting the stromal cells remodeling processes, remain at pre-clinical stages. Development of humanized xenograft mouse models, which overcome the mismatch between human leukemia cells and the mouse BM niche, is required to generate physiologically relevant, patient-specific human niches in mice that can be used to unravel the role of human AML microenvironment and to carry out preclinical studies for the development of new targeted therapies.